$23.28 -0.63 (%) Neurocrine Biosciences Inc - NASDAQ

Dec. 19, 2014 | 09:56 AM

Partner Headlines

  1. Neurocrine Biosciences Reports Expansion of Clinical Pipeline

    Benzinga | Dec. 10, 2014 | 08:02AM EST
  2. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  3. Neurocrine Initiates Tourette Syndrome Clinical Trial

    Benzinga | Oct. 2, 2014 | 16:03PM EST
  4. US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data

    Benzinga | Feb. 27, 2014 | 07:18AM EST
  5. Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX

    GuruFocus | Jan. 13, 2014 | 08:46AM EST
  6. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 8, 2014 | 08:20AM EST
  7. Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report

    Benzinga | Jan. 7, 2014 | 15:43PM EST
  8. Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates

    Benzinga | Jan. 7, 2014 | 11:38AM EST
  9. Benzinga's Volume Movers

    Benzinga | Jan. 7, 2014 | 11:03AM EST
  10. Morning Market Movers

    Benzinga | Jan. 7, 2014 | 10:07AM EST
  11. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD | Jan. 7, 2014 | 09:03AM EST
  12. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 7, 2014 | 08:07AM EST
  13. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study

    Benzinga | Jan. 6, 2014 | 16:02PM EST
  14. Kilroy Realty Acquires Premier Del Mar Office Campus for Approximately $126M

    Benzinga | Sep. 19, 2013 | 19:20PM EST
  15. Market Wrap For Tuesday, September 10: Once Again, China Moves Markets Higher

    Benzinga | Sep. 10, 2013 | 16:22PM EST
  16. Mid-Afternoon Market Update: Apple Releases Two New iPhones, SolarCity Rallies on New Contract

    Benzinga | Sep. 10, 2013 | 15:46PM EST
  17. Mid-Day Market Update: Five Below Shares Gain On Upbeat Results; Urban Outfitters Tumbles

    Benzinga | Sep. 10, 2013 | 12:59PM EST
  18. Mid-Morning Market Update: Markets Rise; McDonald's Global Same-Store Sales Increase 1.9%

    Benzinga | Sep. 10, 2013 | 11:04AM EST
  19. Morning Market Losers

    Benzinga | Sep. 10, 2013 | 10:24AM EST
  20. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 10, 2013 | 08:14AM EST
  21. UPDATE: Deutsche Bank Raises PT on Neurocrine Biosciences Ahead of Key Catalysts

    Benzinga | Aug. 29, 2013 | 08:55AM EST
  22. Neurocrine shares

    IBD | Aug. 21, 2013 | 18:43PM EST
  23. Neurocrine Stock Jumps As Cowen Touts Dyskinesia Drug

    IBD | Aug. 21, 2013 | 12:45PM EST
  24. UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report

    Benzinga | Feb. 11, 2013 | 04:40AM EST
  25. Stocks Hitting 52-Week Highs

    Benzinga | Feb. 11, 2013 | 03:30AM EST
  26. Neurocrine Biosciences Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 8, 2013 | 18:36PM EST
  27. Earnings Scheduled For February 8, 2013

    Benzinga | Feb. 7, 2013 | 19:31PM EST
  28. Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further

    Benzinga | Feb. 5, 2013 | 08:57AM EST
  29. Neurocrine Biosciences Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 31, 2012 | 13:33PM EST
  30. UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

    Benzinga | Oct. 4, 2012 | 08:39AM EST
  31. Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated

    Benzinga | May. 17, 2012 | 10:06AM EST
  32. Neurocrine Biosciences Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 9, 2012 | 07:02AM EST
  33. Top 5 Small-Cap Drug Firms Include Questcor, Cubist

    IBD | Feb. 3, 2012 | 02:14AM EST
  34. Neurocrine Biosciences

    IBD | Jan. 19, 2012 | 11:24AM EST
  35. Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share

    Benzinga | Jan. 19, 2012 | 02:11AM EST
Trading Center